Intralesional collagenase Clostridium histolyticum in the management of Peyronie’s disease: current best practice

The use of Clostridium histolyticum collagenase (CCH) has become increasingly widespread for the treatment of Peyronie’s disease (PD) in recent years. Numerous trials have confirmed both its safety and efficacy in appropriately selected patients with this condition. The purpose of this review is to...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Urology 2018-04, Vol.10 (4), p.139-153
Main Authors: Cwikla, Daniel J., Yafi, Faysal A.
Format: Article
Language:English
Subjects:
Connective tissue diseases
Penis
Reviews
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of Clostridium histolyticum collagenase (CCH) has become increasingly widespread for the treatment of Peyronie’s disease (PD) in recent years. Numerous trials have confirmed both its safety and efficacy in appropriately selected patients with this condition. The purpose of this review is to examine pivotal trials demonstrating the efficacy of CCH, revisit viable candidates for treatment with intralesional injection therapy, and provide a summary of injection technique and appropriate management of patients receiving this treatment at the time of therapy and in follow up.
ISSN:1756-2872
1756-2880
DOI:10.1177/1756287218755020